The DOI matches its Crossref record; 199 of the 199 references it cites were found in a registry or an index.
Evaluation of the use of therapeutic peptides for cancer treatment
Open accessAbstract
Cancer along with cardiovascular disease are the main causes of death in the industrialised countries around the World. Conventional cancer treatments are losing their therapeutic uses due to drug resistance, lack of tumour selectivity and solubility and as such there is a need to develop new therapeutic agents. Therapeutic peptides are a promising and a novel approach to treat many diseases including cancer. They have several advantages over proteins or antibodies: as they are (a) easy to synthesise, (b) have a high target specificity and selectivity and (c) have low toxicity. Therapeutic peptides do have some significant drawbacks related to their stability and short half-life. In this review, strategies used to overcome peptide limitations and to enhance their therapeutic effect will be compared. The use of short cell permeable peptides that interfere and inhibit protein-protein interactions will also be evaluated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
Apoptosis: A Review of Programmed Cell Death
Elmore, S. (2007) · Toxicologic Pathology · doi:10.1080/01926230701320337 · Cited by 13,853
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
The BCL-2 protein family: opposing activities that mediate cell death
Youle, R. J., & Strasser, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2308 · Cited by 4,679
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Interleukin-12 and the regulation of innate resistance and adaptive immunity
Trinchieri, G. (2003) · Nature Reviews Immunology · doi:10.1038/nri1001 · Cited by 3,927
BCL-2 family members and the mitochondria in apoptosis
Gross, A., McDonnell, J. M., & Korsmeyer, S. J. (1999) · Genes & Development · doi:10.1101/gad.13.15.1899 · Cited by 3,641
Cited by
Apoptosis and apoptotic body: disease message and therapeutic target potentials
Xu, X., Lai, Y., & Hua, Z.-C. (2019) · Bioscience Reports · doi:10.1042/bsr20180992 · Cited by 909
Machine intelligence in peptide therapeutics: A next‐generation tool for rapid disease screening
Basith, S., Manavalan, B., Hwan Shin, T., & Lee, G. (2020) · Medicinal Research Reviews · doi:10.1002/med.21658 · Cited by 312
O’Connor, J., Garcia-Vaquero, M., Meaney, S., & Tiwari, B. K. (2022) · Marine Drugs · doi:10.3390/md20050317 · Cited by 81
The C-terminal tail of CSNAP attenuates the CSN complex
Füzesi-Levi, M. G., Ben-Nissan, G., Listov, D., Fridmann Sirkis, Y., Hayouka, Z., Fleishman, S., & Sharon, M. (2023) · Life Science Alliance · doi:10.26508/lsa.202201634 · Cited by 5
New role of bacteriophages in medical oncology
Moradi, M., Ghaleh, H. E. G., Bolandian, M., & Dorostkar, R. (2023) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2506 · Cited by 2
Metadata
- Authors
- Marqus, S., Pirogova, E., & Piva, T. J.
- Venue
- Journal of Biomedical Science
- Published
- 2017-03-21
- Volume
- 24
- Issue
- 1
- Pages
- 21-21
- ISSN
- 1021-7770 (ISSN-L)
- 1423-0127
- OpenAlex
- W2598922467
- Cited by
- 512
- References
- 199
- FWCI
- 13.98
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of the use of therapeutic peptides for cancer treatment. https://app.cochat.ai/papers/10.1186/s12929-017-0328-x
- The paper
- Marqus, S., Pirogova, E., & Piva, T. J. (2017). Evaluation of the use of therapeutic peptides for cancer treatment. Journal of Biomedical Science. https://doi.org/10.1186/s12929-017-0328-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
